I think you made a good suggestion. We begin every study by hearing from the officials. It is particularly important we do that in this case because, quite frankly, I don't think there is anybody on this committee who understands all the changes to the PMPRB.
There is an immense amount of confusion in the general public on what the proposed PMPRB regulatory changes do or don't do, but we're all going to benefit from having a thorough understanding from the experts at the PMPRB of exactly what the changes are before we hear from witnesses.
I have to respectfully disagree with Ms. Rempel Garner. We have not submitted our witnesses. All we had was a deadline for stakeholders to submit their briefs and their desire to appear. The parties have not been invited to submit our witnesses yet, nor have we determined what the allocation of witnesses would be.
The best way forward is to schedule next Monday. Ms. Rempel Garner is correct that we should be moving forward. Why don't we have that meeting next Monday on the PMPRB? We'll hear from the ministry officials to give all of us a chance to grill those officials and have a thorough two-hour understanding of those changes, which is so important for us to have going forward.
We also need to set a deadline for submitting witnesses. Perhaps we can submit witnesses by the end of this week, by Friday, and then the analysts can proceed after that.
I'm not going to open up this debate again, but I will also say to Mr. Thériault that there is nothing in that motion that says the PMPRB study must be completed by any particular time. It's not correct to say that. It said that it has to happen concurrently, and although there are some people who would like to have the PMPRB study done by the Christmas holidays, others do not, and those changes are coming into place in January. Maybe they'll be postponed. They have been postponed twice already, but I'm not undergoing a study on PMPRB to stop them, which I think is the agenda of some people, particularly big pharma in this country. They want to stop the PMPRB changes that are set to come into force on January 1.
That's not this committee's mandate. The committee's mandate is not to do the bidding of big pharma. It is to study the issues, and if we end up studying this issue into February or March and issuing a report to the government, the government can take that report into consideration in March or April and make regulatory changes after that if it sees fit, but I am not marching to the tune of big pharma to do their bidding.
We can get this study under way, which is what our motion called for. We can start the study and examine it concurrently, which means at the same time. We can even have that debate next week as well. I just throw that out now. It's still open to the committee to determine how many meetings we allocate of the remaining six meetings, but let's at least get a start on this, as Mr. Thériault has rightly said. We'll get this started next Monday and hear from the ministry officials.